Month: April 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Wednesday, May 17, 2023 at 16:00 CET (10:00am EDT) at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. All relevant documents and information for the meeting, including the notice and agenda and explanatory notes, are or will be made available in the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Financials and filings” and then “Shareholder meeting”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders...

Uponor Corporation, Investor News, 18 April 2023 at 03:00 pm EEST Invitation: Uponor’s Q1 results briefing on 26 April 2023 Uponor Corporation will publish its interim report for January–March 2023 on Wednesday, 26 April 2023 at around 09:00 am EEST. A live webcast and conference call for analysts, investors and media will be held later on the same day, starting at 02:30 pm EEST at https://uponor.videosync.fi/2023-q1-results, hosted by Uponor Corporation’s President and CEO Michael Rauterkus and CFO Markus Melkko. To ask questions, please participate in the conference call by registering at http://palvelu.flik.fi/teleconference/?id=10010145. After registration you will receive a phone number and conference ID to access the conference call. If you wish to ask a question, please dial *5 on your telephone keypad to enter the queue. All interim...

All 10 patients with late stage melanoma who completed EVX-02 treatment demonstrated robust and treatment-specific immune responses and were relapse-free at their last assessment Results further validate predictive potential of proprietary AI technology and pave the way for advancement of EVX-03, a next-generation DNA-based personalized cancer immunotherapy, into the clinic in Q4COPENHAGEN, Denmark, April 18, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its Phase 1/2a first-in-human study of its DNA-based personalized cancer immunotherapy, EVX-02 in combination with the checkpoint inhibitor nivolumab. Data were presented in the Late Breaking...

The world has lost over 1 trillion trees in the last 100 years. An $11.4 M investment enables Flash Forest mission to plant 1 billion trees by 2028, helping to fight the impacts of climate change MISSISSAUGA, Ontario, April 18, 2023 (GLOBE NEWSWIRE) — Today, Flash Forest, a Canadian reforestation company that uses drones and technology to regenerate post-wildfire areas that are deemed too unsafe for human tree planters, announced the completion of an $11.4 million (CAD) Series A financing round. Climate change is accelerating the frequency and severity of wildfires and we are quickly losing one of our best mechanisms for combating it: trees. Earth loses an average of 26 million hectares of trees every single year. That’s an area roughly the size of Mexico, lost annually. Over 30 per cent of this loss can be attributed to wildfires....

DZS partner Lucas Telecom expertise key to enabling transformation from HFC to high performance and reliable fiber infrastructure capable of delivering gigabit speeds DALLAS, April 18, 2023 (GLOBE NEWSWIRE) — DZS (Nasdaq: DZSI), a global leader of access, optical and cloud-controlled software solutions, today announced that St. Kitts-Nevis Cable Communications Ltd. (The Cable), a leading local provider of internet and television services, is leveraging DZS Velocity Optical Line Terminals (OLTs) and DZS Helix Optical Networking Terminals (ONTs) to replace its existing legacy Hybrid Fiber-Coaxial (HFC) cable network with a world-class, all-fiber Gigabit Passive Optical network (GPON) capable of delivering gigabit broadband speeds. This network and services transformation is being enabled by longtime DZS partner Lucas Telecom, and...

TORONTO and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — AcuityAds Holdings Inc. (TSX: ILLM, Nasdaq: ILLM), a leading digital advertising software company focusing on journey advertising, (the “Company” or “illumin”) announced today that it has rebranded to illumin, the namesake of its revolutionary platform. As part of this rebranding, while the Company retains its legal name “AcuityAds Holdings Inc.”, it will now be doing business as “illumin”. The Company’s new brand name reflects the platform’s success and adoption in the market, and the company’s mission to illuminate the path for brands to connect with their customers through the power of data-driven advertising. illumin’s journey advertising platform enables brands and agencies to reach consumers at every stage of the marketing journey from awareness to conversion. Using...

Shanghai Volkswagen Automotive Co. (SVW) and FAW-Volkswagen (FAW-VW) will leverage Cerence’s multi-lingual solutions to deliver safer, more convenient in-car experiences BURLINGTON, Mass., April 18, 2023 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced that Chinese smart car supplier Banma has tapped Cerence to bring advanced in-car conversational AI and voice recognition technology to Banma’s automaker customers, including Shanghai Volkswagen Automotive Co. (SVW) and FAW-Volkswagen (FAW-VW). Banma provides smart car operating systems and digital transportation solutions for the automotive and transportation industries. By partnering with Cerence, Banma can deliver its key customers market-leading voice recognition and AI-powered, in-car intelligence solutions, enabling them to create unique...

Results published in Journal of Trauma and Acute Care Surgery Company also provides update on enrollment progress in Phase 2/3 vascular trauma trial DURHAM, N.C., April 18, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced the publication of a preclinical study in the Journal of Trauma and Acute Care Surgery comparing the use of its Human Acellular Vessel (HAV) to expanded polytetrafluorethylene (ePTFE) grafts for vascular repair following arterial trauma. In the preclinical study the HAV performed better than ePTFE on multiple indices. In this comparative preclinical study, 36 pigs were randomly assigned to treatment groups receiving either the HAV or an ePTFE graft to reconstruct a...

NORCROSS, Ga., April 18, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic Conference on NASH Cirrhosis: From Mechanisms to Management, sponsored by the American Association for the Study of Liver Diseases (AASLD). The Conference took place in Los Angeles, March 25-26, 2023. The AASLD has created a new forum to share knowledge around NASH cirrhosis and explore current and future opportunities for patients affected with this devastating disease. Currently, the only curative treatment for patients is a liver transplantation, an expensive procedure whose access is extraordinarily limited. The conference was attended by members of the AASLD Hepatology Community who have a special interest in liver cirrhosis due to...

MARIETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the first quarter ended March 31, 2023 after the market close on Tuesday, May 2, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13737183 A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event. About MIMEDXMIMEDX is a pioneer and leader in placental...